Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer

G. Minniti, M. Salvati, R. Muni, G. Lanzetta, M. F. Osti, E. Clarke, A. Costa, A. Bozzao, G. Trasimeni, R. Maurizi Enrici

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC). Patients and Methods: Between June 2004 and September 2008, sixty-six patients with multiple brain metastases from NSCLC were enrolled in this prospective study. All patients were required to have 2-3 brain metastases and Karnofsky performance status (KPS) ≥70. WBRT treatment dose was 30 Gy in 10 fractions followed by SRS. A matched control population treated with WBRT alone to a dose of 30 Gy in 10 fractions was used for comparison. Results: The median survival was 10.3 months in the WBRT plus SRS group and 7.2 months in the WBRT group (p=0.005). The 6-month and 12-month survival rates were 90% and 38% in the SRS plus WBRT group and 84% and 19% in the WBRT group (p=0.01). Stable extracranial disease and KPS were significant predictive factors of survival in both groups (p=0.001). Death due to neurological causes occurred in 18% and 35% of patients treated with WBRT plus SRS and WBRT (p=0.02), respectively. Disease control in the brain was 10 months in the SRS plus WBRT group and 7 months in the WBRT group (p=0.001); the 6-month and 12-month control rates were 82% and 42% for WBRT plus SRS, and 75% and 18% for WBRT (p=0.001), respectively. The 6-month and 12-month control rates of treated lesions (local control) were 90% and 47% in the WBRT group, and 100% and 93% in the WBRT plus SRS group (p=0.001). Conclusion: WBRT plus SRS is a safe, minimally invasive and well-tolerated treatment for patients with up to three brain metastases from NSCLC. The treatment is associated with longer survival and better disease control in comparison with WBRT alone. Survival benefits need to be confirmed by large randomized studies.

Original languageEnglish
Pages (from-to)3055-3061
Number of pages7
JournalAnticancer Research
Volume30
Issue number7
Publication statusPublished - Jul 2010

Fingerprint

Radiosurgery
Non-Small Cell Lung Carcinoma
Radiotherapy
Neoplasm Metastasis
Brain
Therapeutics
Karnofsky Performance Status
Survival
Survival Rate

Keywords

  • Multiple brain metastases
  • Non small-cell lung cancer
  • Radiotherapy
  • Stereotactic radiosurgery
  • Survival
  • Whole brain radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Minniti, G., Salvati, M., Muni, R., Lanzetta, G., Osti, M. F., Clarke, E., ... Maurizi Enrici, R. (2010). Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. Anticancer Research, 30(7), 3055-3061.

Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. / Minniti, G.; Salvati, M.; Muni, R.; Lanzetta, G.; Osti, M. F.; Clarke, E.; Costa, A.; Bozzao, A.; Trasimeni, G.; Maurizi Enrici, R.

In: Anticancer Research, Vol. 30, No. 7, 07.2010, p. 3055-3061.

Research output: Contribution to journalArticle

Minniti, G, Salvati, M, Muni, R, Lanzetta, G, Osti, MF, Clarke, E, Costa, A, Bozzao, A, Trasimeni, G & Maurizi Enrici, R 2010, 'Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer', Anticancer Research, vol. 30, no. 7, pp. 3055-3061.
Minniti G, Salvati M, Muni R, Lanzetta G, Osti MF, Clarke E et al. Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. Anticancer Research. 2010 Jul;30(7):3055-3061.
Minniti, G. ; Salvati, M. ; Muni, R. ; Lanzetta, G. ; Osti, M. F. ; Clarke, E. ; Costa, A. ; Bozzao, A. ; Trasimeni, G. ; Maurizi Enrici, R. / Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. In: Anticancer Research. 2010 ; Vol. 30, No. 7. pp. 3055-3061.
@article{b2f7a2415cb04301bbece462473fcd54,
title = "Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer",
abstract = "Background: The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC). Patients and Methods: Between June 2004 and September 2008, sixty-six patients with multiple brain metastases from NSCLC were enrolled in this prospective study. All patients were required to have 2-3 brain metastases and Karnofsky performance status (KPS) ≥70. WBRT treatment dose was 30 Gy in 10 fractions followed by SRS. A matched control population treated with WBRT alone to a dose of 30 Gy in 10 fractions was used for comparison. Results: The median survival was 10.3 months in the WBRT plus SRS group and 7.2 months in the WBRT group (p=0.005). The 6-month and 12-month survival rates were 90{\%} and 38{\%} in the SRS plus WBRT group and 84{\%} and 19{\%} in the WBRT group (p=0.01). Stable extracranial disease and KPS were significant predictive factors of survival in both groups (p=0.001). Death due to neurological causes occurred in 18{\%} and 35{\%} of patients treated with WBRT plus SRS and WBRT (p=0.02), respectively. Disease control in the brain was 10 months in the SRS plus WBRT group and 7 months in the WBRT group (p=0.001); the 6-month and 12-month control rates were 82{\%} and 42{\%} for WBRT plus SRS, and 75{\%} and 18{\%} for WBRT (p=0.001), respectively. The 6-month and 12-month control rates of treated lesions (local control) were 90{\%} and 47{\%} in the WBRT group, and 100{\%} and 93{\%} in the WBRT plus SRS group (p=0.001). Conclusion: WBRT plus SRS is a safe, minimally invasive and well-tolerated treatment for patients with up to three brain metastases from NSCLC. The treatment is associated with longer survival and better disease control in comparison with WBRT alone. Survival benefits need to be confirmed by large randomized studies.",
keywords = "Multiple brain metastases, Non small-cell lung cancer, Radiotherapy, Stereotactic radiosurgery, Survival, Whole brain radiotherapy",
author = "G. Minniti and M. Salvati and R. Muni and G. Lanzetta and Osti, {M. F.} and E. Clarke and A. Costa and A. Bozzao and G. Trasimeni and {Maurizi Enrici}, R.",
year = "2010",
month = "7",
language = "English",
volume = "30",
pages = "3055--3061",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer

AU - Minniti, G.

AU - Salvati, M.

AU - Muni, R.

AU - Lanzetta, G.

AU - Osti, M. F.

AU - Clarke, E.

AU - Costa, A.

AU - Bozzao, A.

AU - Trasimeni, G.

AU - Maurizi Enrici, R.

PY - 2010/7

Y1 - 2010/7

N2 - Background: The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC). Patients and Methods: Between June 2004 and September 2008, sixty-six patients with multiple brain metastases from NSCLC were enrolled in this prospective study. All patients were required to have 2-3 brain metastases and Karnofsky performance status (KPS) ≥70. WBRT treatment dose was 30 Gy in 10 fractions followed by SRS. A matched control population treated with WBRT alone to a dose of 30 Gy in 10 fractions was used for comparison. Results: The median survival was 10.3 months in the WBRT plus SRS group and 7.2 months in the WBRT group (p=0.005). The 6-month and 12-month survival rates were 90% and 38% in the SRS plus WBRT group and 84% and 19% in the WBRT group (p=0.01). Stable extracranial disease and KPS were significant predictive factors of survival in both groups (p=0.001). Death due to neurological causes occurred in 18% and 35% of patients treated with WBRT plus SRS and WBRT (p=0.02), respectively. Disease control in the brain was 10 months in the SRS plus WBRT group and 7 months in the WBRT group (p=0.001); the 6-month and 12-month control rates were 82% and 42% for WBRT plus SRS, and 75% and 18% for WBRT (p=0.001), respectively. The 6-month and 12-month control rates of treated lesions (local control) were 90% and 47% in the WBRT group, and 100% and 93% in the WBRT plus SRS group (p=0.001). Conclusion: WBRT plus SRS is a safe, minimally invasive and well-tolerated treatment for patients with up to three brain metastases from NSCLC. The treatment is associated with longer survival and better disease control in comparison with WBRT alone. Survival benefits need to be confirmed by large randomized studies.

AB - Background: The aim of this study was to evaluate local control and survival rates after stereotactic radiosurgery (SRS) plus whole-brain radiotherapy (WBRT) for the treatment of multiple brain metastases from non-small cell lung cancer (NSCLC). Patients and Methods: Between June 2004 and September 2008, sixty-six patients with multiple brain metastases from NSCLC were enrolled in this prospective study. All patients were required to have 2-3 brain metastases and Karnofsky performance status (KPS) ≥70. WBRT treatment dose was 30 Gy in 10 fractions followed by SRS. A matched control population treated with WBRT alone to a dose of 30 Gy in 10 fractions was used for comparison. Results: The median survival was 10.3 months in the WBRT plus SRS group and 7.2 months in the WBRT group (p=0.005). The 6-month and 12-month survival rates were 90% and 38% in the SRS plus WBRT group and 84% and 19% in the WBRT group (p=0.01). Stable extracranial disease and KPS were significant predictive factors of survival in both groups (p=0.001). Death due to neurological causes occurred in 18% and 35% of patients treated with WBRT plus SRS and WBRT (p=0.02), respectively. Disease control in the brain was 10 months in the SRS plus WBRT group and 7 months in the WBRT group (p=0.001); the 6-month and 12-month control rates were 82% and 42% for WBRT plus SRS, and 75% and 18% for WBRT (p=0.001), respectively. The 6-month and 12-month control rates of treated lesions (local control) were 90% and 47% in the WBRT group, and 100% and 93% in the WBRT plus SRS group (p=0.001). Conclusion: WBRT plus SRS is a safe, minimally invasive and well-tolerated treatment for patients with up to three brain metastases from NSCLC. The treatment is associated with longer survival and better disease control in comparison with WBRT alone. Survival benefits need to be confirmed by large randomized studies.

KW - Multiple brain metastases

KW - Non small-cell lung cancer

KW - Radiotherapy

KW - Stereotactic radiosurgery

KW - Survival

KW - Whole brain radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=77955787619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955787619&partnerID=8YFLogxK

M3 - Article

C2 - 20683055

AN - SCOPUS:77955787619

VL - 30

SP - 3055

EP - 3061

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -